|
EE200000706A
(et)
|
1998-05-26 |
2002-06-17 |
Warner-Lambert Company |
Bitsüklilised pürimidiinid ja bitsüklilised 3,4-dihüdropürimidiinid kui rakkude proliferatsiooni inhibiitorid
|
|
HK1041483B
(zh)
*
|
1998-10-23 |
2004-12-24 |
霍夫曼-拉罗奇有限公司 |
雙環氮雜環
|
|
KR100523120B1
(ko)
*
|
1999-10-21 |
2005-10-20 |
에프. 호프만-라 로슈 아게 |
P38 단백질 키나제 저해제로서 헤테로알킬아미노-치환된이환 질소 헤테로환
|
|
DE60032623T2
(de)
*
|
1999-10-21 |
2007-10-11 |
F. Hoffmann-La Roche Ag |
Alkylamino-substituierte bicyclische heterocyclen als p38 protein-kinase-inhibitoren
|
|
OA12316A
(en)
|
2000-01-24 |
2006-05-15 |
Warner Lambert Co |
3-Aminoquinazolin-2,4-dione antibacterial agents.
|
|
CA2397961C
(en)
*
|
2000-01-25 |
2008-08-26 |
Richard John Booth |
Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
|
|
US7053070B2
(en)
|
2000-01-25 |
2006-05-30 |
Warner-Lambert Company |
Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
|
|
US7235551B2
(en)
|
2000-03-02 |
2007-06-26 |
Smithkline Beecham Corporation |
1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
|
|
MY141144A
(en)
*
|
2000-03-02 |
2010-03-15 |
Smithkline Beecham Corp |
1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
|
|
YU66502A
(sh)
*
|
2000-03-06 |
2005-09-19 |
Warner-Lambert Company |
5-alkilpirido(2,3-d)pirimidini, inhibitori tirozinkinaza
|
|
CA2420286A1
(en)
*
|
2000-08-31 |
2002-03-07 |
F. Hoffmann-La Roche Ag |
7-oxo pyridopyrimidines as inhibitors of a cellular proliferation
|
|
US6506749B2
(en)
|
2000-08-31 |
2003-01-14 |
Syntex (U.S.A.) Llc |
7-oxo-pyridopyrimidines (I)
|
|
JP4524072B2
(ja)
|
2000-10-23 |
2010-08-11 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
新規化合物
|
|
GB0029015D0
(en)
|
2000-11-28 |
2001-01-10 |
Univ London |
Medical device
|
|
ATE320255T1
(de)
|
2001-01-19 |
2006-04-15 |
Smithkline Beecham Corp |
Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
|
|
CZ20032416A3
(cs)
|
2001-02-12 |
2004-07-14 |
F. Hoffmann-La Roche Ag |
6-Substituované pyridopyrimidiny
|
|
US7105667B2
(en)
|
2001-05-01 |
2006-09-12 |
Bristol-Myers Squibb Co. |
Fused heterocyclic compounds and use thereof
|
|
ATE315038T1
(de)
|
2001-05-30 |
2006-02-15 |
Warner Lambert Co |
Antibakterielle mittel
|
|
DE60303009T2
(de)
*
|
2002-01-22 |
2006-07-13 |
Warner-Lambert Co. Llc |
2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-one
|
|
US7176310B1
(en)
|
2002-04-09 |
2007-02-13 |
Ucb Sa |
Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
|
|
MXPA04010267A
(es)
|
2002-04-19 |
2005-02-03 |
Smithkline Beecham Corp |
Compuestos novedosos.
|
|
PA8577501A1
(es)
|
2002-07-25 |
2004-02-07 |
Warner Lambert Co |
Inhibidores de quinasas
|
|
RU2324695C2
(ru)
|
2002-08-06 |
2008-05-20 |
Ф.Хоффманн-Ля Рош Аг |
6-АЛКОКСИПИРИДОПИРИМИДИНЫ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АКТИВНОСТЬЮ ИНГИБИТОРОВ КИНАЗЫ МАР р38
|
|
US7084270B2
(en)
*
|
2002-08-14 |
2006-08-01 |
Hoffman-La Roche Inc. |
Pyrimido compounds having antiproliferative activity
|
|
US7112676B2
(en)
*
|
2002-11-04 |
2006-09-26 |
Hoffmann-La Roche Inc. |
Pyrimido compounds having antiproliferative activity
|
|
TW200413381A
(en)
|
2002-11-04 |
2004-08-01 |
Hoffmann La Roche |
Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents
|
|
JP2006516561A
(ja)
*
|
2003-01-17 |
2006-07-06 |
ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー |
細胞増殖の阻害剤としての2−アミノピリジン置換ヘテロ環類
|
|
CN100497339C
(zh)
*
|
2003-04-10 |
2009-06-10 |
霍夫曼-拉罗奇有限公司 |
嘧啶并化合物
|
|
DE10325133A1
(de)
*
|
2003-06-04 |
2004-12-23 |
Bayer Cropscience Ag |
Triazolopyrimidine
|
|
BRPI0413005A
(pt)
|
2003-07-29 |
2006-09-26 |
Irm Llc |
compostos e composições como inibidores da proteìna cinase
|
|
WO2005047284A1
(en)
|
2003-11-13 |
2005-05-26 |
F. Hoffmann-La Roche Ag |
Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
|
|
JP4812763B2
(ja)
*
|
2004-05-18 |
2011-11-09 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途
|
|
WO2006024486A2
(en)
|
2004-08-31 |
2006-03-09 |
F. Hoffmann-La Roche Ag |
Amide derivatives of 3-phenyl dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents
|
|
CN1984914A
(zh)
|
2004-08-31 |
2007-06-20 |
霍夫曼-拉罗奇有限公司 |
7-氨基-3-苯基-二氢嘧啶并[4,5-d]嘧啶酮的酰胺衍生物、其制备和作为蛋白激酶抑制剂的应用
|
|
EP1828186A1
(en)
|
2004-12-13 |
2007-09-05 |
Sunesis Pharmaceuticals, Inc. |
Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
|
|
PE20061193A1
(es)
|
2005-03-25 |
2006-12-02 |
Glaxo Group Ltd |
DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
|
|
US20090137550A1
(en)
|
2005-03-25 |
2009-05-28 |
Glaxo Group Limited |
Novel Compounds
|
|
MY145343A
(en)
|
2005-03-25 |
2012-01-31 |
Glaxo Group Ltd |
Novel compounds
|
|
US20080096905A1
(en)
|
2005-03-25 |
2008-04-24 |
Glaxo Group Limited |
Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives
|
|
ES2329419T3
(es)
|
2006-01-31 |
2009-11-25 |
F. Hoffmann-La Roche Ag |
7h-pirido(3,4-d)pirimidin-8-onas, su preparacion y uso como inhibidores de proteinas cinasas.
|
|
CN101784551A
(zh)
*
|
2007-06-15 |
2010-07-21 |
万有制药株式会社 |
二环苯胺衍生物
|
|
US8071766B2
(en)
|
2008-02-01 |
2011-12-06 |
Takeda Pharmaceutical Company Limited |
HSP90 inhibitors
|
|
WO2010067888A1
(en)
*
|
2008-12-12 |
2010-06-17 |
Banyu Pharmaceutical Co.,Ltd. |
Dihydropyrimidopyrimidine derivatives
|
|
WO2010067886A1
(en)
*
|
2008-12-12 |
2010-06-17 |
Banyu Pharmaceutical Co.,Ltd. |
Dihydropyrimidopyrimidine derivative
|
|
EP2379559B1
(en)
*
|
2009-01-06 |
2017-10-25 |
Dana-Farber Cancer Institute, Inc. |
Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
|
|
JP2012518598A
(ja)
*
|
2009-02-25 |
2012-08-16 |
Msd株式会社 |
ピリミドピリミドインダゾール誘導体
|
|
SA111320200B1
(ar)
|
2010-02-17 |
2014-02-16 |
ديبيوفارم اس ايه |
مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
|
|
DK2600719T3
(da)
*
|
2010-08-05 |
2014-12-15 |
Univ Temple |
2-substituerede 8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-carbonnitriler og anvendelser deraf
|
|
WO2012088266A2
(en)
|
2010-12-22 |
2012-06-28 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
|
|
AU2012245387C1
(en)
|
2011-04-22 |
2016-05-05 |
Signal Pharmaceuticals, Llc |
Substituted Diaminocarboxamide and Diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
|
|
CN103974938B
(zh)
|
2011-10-14 |
2016-11-09 |
百时美施贵宝公司 |
作为因子xia抑制剂的经取代的四氢异喹啉化合物
|
|
IN2014CN02805A
(is)
|
2011-10-14 |
2015-07-03 |
Bristol Myers Squibb Co |
|
|
ES2699226T3
(es)
|
2011-10-14 |
2019-02-08 |
Bristol Myers Squibb Co |
Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa
|
|
US9611267B2
(en)
*
|
2012-06-13 |
2017-04-04 |
Incyte Holdings Corporation |
Substituted tricyclic compounds as FGFR inhibitors
|
|
DK2872491T3
(da)
*
|
2012-07-11 |
2021-08-09 |
Blueprint Medicines Corp |
Inhibitorer af fibroblastvækstfaktorreceptoren
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
WO2014059214A1
(en)
|
2012-10-12 |
2014-04-17 |
Bristol-Myers Squibb Company |
Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
|
|
US9315519B2
(en)
|
2012-10-12 |
2016-04-19 |
Bristol-Myers Squibb Company |
Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
|
|
JP6154473B2
(ja)
|
2012-10-12 |
2017-06-28 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
第XIa因子阻害剤の結晶形
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
US9321786B2
(en)
|
2013-03-15 |
2016-04-26 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
EP3943087A1
(en)
|
2013-03-15 |
2022-01-26 |
Celgene CAR LLC |
Heteroaryl compounds and uses thereof
|
|
ES2712699T3
(es)
|
2013-03-25 |
2019-05-14 |
Bristol Myers Squibb Co |
Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa
|
|
TWI649318B
(zh)
|
2013-04-19 |
2019-02-01 |
英塞特控股公司 |
作為fgfr抑制劑之雙環雜環
|
|
WO2015006492A1
(en)
|
2013-07-09 |
2015-01-15 |
Dana-Farber Cancer Institute, Inc. |
Kinase inhibitors for the treatment of disease
|
|
LT3057943T
(lt)
|
2013-10-18 |
2018-11-12 |
Eisai R&D Management Co., Ltd. |
Pirimidino fgfr4 slopikliai
|
|
BR112016008849B8
(pt)
|
2013-10-25 |
2022-09-06 |
Blueprint Medicines Corp |
Compostos ou sais farmaceuticamente aceitáveis dos mesmos, uso dos referidos compostos e composições farmacêuticas
|
|
RU2016129380A
(ru)
|
2013-12-20 |
2018-01-25 |
СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
Замещенные диаминопиримидильные соединения, их композиции и способы лечения с их участием
|
|
NO2760821T3
(is)
|
2014-01-31 |
2018-03-10 |
|
|
|
TWI688564B
(zh)
|
2014-01-31 |
2020-03-21 |
美商必治妥美雅史谷比公司 |
作為凝血因子xia抑制劑之具有雜環p2'基團之巨環化合物
|
|
CN103880861B
(zh)
*
|
2014-02-21 |
2016-02-03 |
温州医科大学 |
一种作用于FGF受体的4,6-二甲基-噁唑并[5,4-d]嘧啶-5,7(4H,6H)-二酮衍生物
|
|
MA38393B1
(fr)
|
2014-03-13 |
2018-11-30 |
Sanofi Sa |
Composés hétéroaryle et utilisations associées
|
|
WO2016036893A1
(en)
|
2014-09-04 |
2016-03-10 |
Bristol-Myers Squibb Company |
Diamide macrocycles that are fxia inhibitors
|
|
US9453018B2
(en)
|
2014-10-01 |
2016-09-27 |
Bristol-Myers Squibb Company |
Pyrimidinones as factor XIa inhibitors
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
|
AU2016219822B2
(en)
|
2015-02-20 |
2020-07-09 |
Incyte Holdings Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2016168331A1
(en)
|
2015-04-14 |
2016-10-20 |
Eisai R&D Management Co., Ltd. |
Crystalline fgfr4 inhibitor compound and uses thereof
|
|
JP7372740B2
(ja)
|
2016-05-10 |
2023-11-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
細胞生存性及び/又は細胞増殖を低減するための薬物の組み合わせ
|
|
CN107459519A
(zh)
*
|
2016-06-06 |
2017-12-12 |
上海艾力斯医药科技有限公司 |
稠合嘧啶哌啶环衍生物及其制备方法和应用
|
|
US10954242B2
(en)
|
2016-07-05 |
2021-03-23 |
The Broad Institute, Inc. |
Bicyclic urea kinase inhibitors and uses thereof
|
|
TWI808958B
(zh)
|
2017-01-25 |
2023-07-21 |
美商特普醫葯公司 |
涉及二芳基巨環化合物之組合療法
|
|
US11285158B2
(en)
|
2017-02-28 |
2022-03-29 |
The General Hospital Corporation |
Uses of pyrimidopyrimidinones as SIK inhibitors
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
ES2991427T3
(es)
|
2018-05-04 |
2024-12-03 |
Incyte Corp |
Formas sólidas de un inhibidor de FGFR y procedimientos para preparar las mismas
|
|
TW201946630A
(zh)
|
2018-05-04 |
2019-12-16 |
美商英塞特公司 |
Fgfr抑制劑之鹽
|
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
GEAP202415945A
(en)
|
2019-10-14 |
2024-04-25 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
GB201915828D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
AU2020395185A1
(en)
|
2019-12-04 |
2022-06-02 |
Incyte Corporation |
Derivatives of an FGFR inhibitor
|
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
US20230295114A1
(en)
*
|
2020-05-08 |
2023-09-21 |
Georgiamune Llc |
Akt3 modulators
|
|
US11753413B2
(en)
|
2020-06-19 |
2023-09-12 |
Incyte Corporation |
Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
|
|
WO2021257857A1
(en)
|
2020-06-19 |
2021-12-23 |
Incyte Corporation |
Naphthyridinone compounds as jak2 v617f inhibitors
|
|
US11767323B2
(en)
|
2020-07-02 |
2023-09-26 |
Incyte Corporation |
Tricyclic pyridone compounds as JAK2 V617F inhibitors
|
|
KR20230057341A
(ko)
|
2020-07-02 |
2023-04-28 |
인사이트 코포레이션 |
Jak2 v617f 억제제로서 삼환계 우레아 화합물
|
|
WO2022046989A1
(en)
|
2020-08-27 |
2022-03-03 |
Incyte Corporation |
Tricyclic urea compounds as jak2 v617f inhibitors
|
|
CN116529251A
(zh)
*
|
2020-12-02 |
2023-08-01 |
上海瑛派药业有限公司 |
取代的稠合双环化合物作为激酶抑制剂及其应用
|
|
WO2022140231A1
(en)
|
2020-12-21 |
2022-06-30 |
Incyte Corporation |
Deazaguaine compounds as jak2 v617f inhibitors
|
|
AR125273A1
(es)
|
2021-02-25 |
2023-07-05 |
Incyte Corp |
Lactamas espirocíclicas como inhibidores de jak2 v617f
|
|
EP4323405A1
(en)
|
2021-04-12 |
2024-02-21 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
AR126101A1
(es)
|
2021-06-09 |
2023-09-13 |
Incyte Corp |
Heterociclos tricíclicos como inhibidores de fgfr
|
|
CA3220274A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
PE20251706A1
(es)
|
2022-03-17 |
2025-07-02 |
Incyte Corp |
Compuestos de urea triciclica como inhibidores de v617f de jak2
|
|
WO2024199388A1
(zh)
*
|
2023-03-29 |
2024-10-03 |
微境生物医药科技(上海)有限公司 |
作为myt1抑制剂的化合物
|
|
WO2026024674A1
(en)
|
2024-07-22 |
2026-01-29 |
Genesis Therapeutics, Inc. |
Methods of treating skp2-associated cancers
|